Payment overview · 2025
General Payments
$248.99
14 reported records · 9 companies
Healthcare provider profile · identity verified
William Mcpeters, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALBANY, GA · NPI 1396849766
Verified facts
What the public records show
CMS Open Payments records show William Mcpeters, M.D. received $248.99 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.03 | 38.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.33 | 15.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $24.91 | 10.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.98 | 8.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.12 | 8.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.37 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.07 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.60 | 5.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.58 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.99 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 215 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
215 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 986 | 290 |
| Atorvastatin Calcium | Atorvastatin Calcium | 890 | 256 |
| Losartan Potassium | Losartan Potassium | 548 | 138 |
| Lisinopril | Lisinopril | 413 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 407 | 122 |
| Gabapentin | Gabapentin | 401 | 132 |
| Metformin Hcl | Metformin Hcl | 384 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 338 | 90 |
| Tramadol Hcl | Tramadol Hcl | 328 | 64 |
| Furosemide | Furosemide | 321 | 100 |
| Omeprazole | Omeprazole | 317 | 99 |
| Potassium Chloride | Potassium Chloride | 245 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 225 | 91 |
| Ozempic | Semaglutide | 215 | 44 |
| Famotidine | Famotidine | 211 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 191 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 189 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 57 |
| Carvedilol | Carvedilol | 168 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 38 |
| Simvastatin | Simvastatin | 154 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 53 |
| Glimepiride | Glimepiride | 142 | 39 |
| Eliquis | Apixaban | 130 | 39 |
| Meloxicam | Meloxicam | 130 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 34 |
| Januvia | Sitagliptin Phosphate | 118 | 26 |
| Allopurinol | Allopurinol | 114 | 30 |
| Montelukast Sodium | Montelukast Sodium | 113 | 30 |
| Nifedipine Er | Nifedipine | 109 | 32 |
| Glipizide | Glipizide | 106 | 28 |
| Trulicity | Dulaglutide | 106 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 29 |
| Trazodone Hcl | Trazodone Hcl | 102 | 30 |
| Atenolol | Atenolol | 99 | 30 |
| Colchicine | Colchicine | 97 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 25 |
| Metformin Hcl Er | Metformin Hcl | 90 | 22 |
| Jardiance | Empagliflozin | 89 | 23 |
| Levetiracetam | Levetiracetam | 85 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 23 |
| Spironolactone | Spironolactone | 71 | 21 |
| Lovastatin | Lovastatin | 69 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 67 | 16 |
| Naproxen | Naproxen | 67 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 18 |
| Meclizine Hcl | Meclizine Hcl | 64 | 25 |
| Fluconazole | Fluconazole | 62 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 19 |
| Valsartan | Valsartan | 56 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Glipizide Er | Glipizide | 49 | 15 |
| Azithromycin | Azithromycin | 47 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 21 |
| Prednisone | Prednisone | 45 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 15 |
| Ibuprofen | Ibuprofen | 41 | 16 |
| Celecoxib | Celecoxib | 40 | 17 |
| Pregabalin | Pregabalin | 39 | 14 |
| Chlorthalidone | Chlorthalidone | 38 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 34 |
| Mirtazapine | Mirtazapine | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 31 | 11 |
| Xarelto | Rivaroxaban | 31 | 12 |
| Azelastine Hcl | Azelastine Hcl | 29 | 16 |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 15 |
| Baclofen | Baclofen | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.99 · 14 records | Novo Nordisk Inc | Dexcom G6 Transmitter, JOURNAVX, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error